Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock in the Biotechnology Industry, returning 12,482.3%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 12,482.34% |
Abivax SA American Depositary Shares (ABVX) | 1,195.17% |
Protagenic Therapeutics (PTIXW) | 669.23% |
Nanobiotix (NBTX) | 658.84% |
Palvella Therapeutics (PVLA) | 502.07% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 467.49% |
I-Mab (IMAB) | 461.18% |
ABVC BioPharma (ABVC) | 415.25% |
Neuphoria Therapeutics (NEUP) | 379.45% |
DBV Technologies (DBVT) | 355.93% |
Lixte Biotechnology (LIXTW) | 350% |
Ainos (AIMDW) | 325.96% |
Cidara Therapeutics (CDTX) | 317% |
Monopar Therapeutics (MNPR) | 299.18% |
Quantum BioPharma (QNTM) | 281.84% |
Invivyd (IVVD) | 274.47% |
ATAI Life Sciences (ATAI) | 272.26% |
GRAIL, LLC (GRAL) | 271.1% |
Galectin Therapeutics (GALT) | 260.31% |
Celcuity LLC (CELC) | 248.49% |
Uniqure (QURE) | 244.85% |
Mineralys Therapeutics, Inc Common Stock (MLYS) | 241.93% |
Matinas BioPharma (MTNB) | 240.64% |
CervoMed (CRVO) | 239.58% |
CytomX Therapeutics (CTMX) | 232.67% |
